The ASSURE Study: HIV-1 Suppression Is Maintained with Bone and Renal Biomarker Improvement 48 Weeks after Ritonavir Discontinuation and Randomized Switch to Abacavir/Lamivudine + Atazanavir. HIV Medicine, 17(2): 106-117.
This website uses cookies to improve your experience. We’ll assume you’re ok with this, but you can opt-out if you wish. [cookie_settings] [cookie_button]
